SCHEMBL1853644

SCHEMBL1853644

O=C1CCc2nc(N3CCOCC3)sc21

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 9/20 0.83
PIK3CA P42336 9/20 0.83
PIK3CB P42338 9/20 0.83
PIK3CG P48736 7/20 0.83
SMN1; SMN2 Q16637 5/20 0.60
HTT P42858 1/20 0.51
HIF1A Q16665 1/20 0.51
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
ALDH1A1 P00352 4/20 0.44
ALOX15 P16050 2/20 0.40
MAPT P10636 3/20 0.40
GAA P10253 2/20 0.40
KDM4E B2RXH2 1/20 0.40
TP53 P04637 2/20 0.39
USP2 O75604 1/20 0.39
PKM P14618 1/20 0.39
AR P10275 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL303137 0.91 PIK3CD (1.00) PIK3CDPIK3CAPIK3CBPIK3CGSMN1; SMN2
SCHEMBL1853490 0.80 HTT (0.64) PIK3CDPIK3CAPIK3CBPIK3CGSMN1; SMN2
SCHEMBL12865395 0.78 PIK3CD (0.74) PIK3CDPIK3CAPIK3CBPIK3CGSMN1; SMN2
SCHEMBL304345 0.78 PIK3CA (1.00) PIK3CDPIK3CAPIK3CBPIK3CGSMN1; SMN2
SCHEMBL1176987 0.78 PIK3CD (1.00) PIK3CDPIK3CAPIK3CBPIK3CGSMN1; SMN2
SCHEMBL1177420 0.77 PIK3CD (0.59) PIK3CDPIK3CAPIK3CBPIK3CGSMN1; SMN2
SCHEMBL1177184 0.77 PIK3CD (0.59) PIK3CDPIK3CAPIK3CBPIK3CGSMN1; SMN2
SCHEMBL303576 0.77 PIK3CD (0.67) PIK3CDPIK3CAPIK3CBPIK3CGSMN1; SMN2
SCHEMBL1177072 0.76 PIK3CA (1.00) PIK3CDPIK3CAPIK3CBPIK3CGSMN1; SMN2
SCHEMBL1177596 0.75 PIK3CD (0.70) PIK3CDPIK3CAPIK3CBPIK3CGSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA PIK3CD 15/4885PIK3CA 3/4885PIK3CB 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.